contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


xbrane-has-released-the-companys-2025-annual-and-sustainability-report-the-report-summarizes-business-financial-performance-and-work-on-sustainability

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

Navnet er sigende - udtales “ex-brain” - her investerer dem, der HAVDE en hjerne. Inklusive mig, desværre.

Er dette firma altså medicinalindustriens egen Summa Defence fra Sverige?

Det er irriterende, når det omvendte split ikke bliver ordentligt bemærket. Men der kommer jo stadig intet ud af det firmas forløb.

Xbrane advarer om, at selskabet vil være insolvent om et par måneder, hvis de ønskede finansieringsløsninger ikke opnås, og selskabet ikke får licenseret Xdivane™ og/eller XB003-kandidaterne inden udgangen af oktober.  Som meddelt den 1. august 2024 og i lyset af den tidligere meddelte forsinkelse i FDA-godkendelsen af Ximluci® og den uforudsete opsigelse af licensaftalen med Biogen, har Xbrane Biopharma AB (publ) (“Xbrane” eller “Selskabet”) indledt en proces med henblik på at udlicensere både Xdivane™ og XB003 for at sikre finansiering indtil det forventede positive operationelle cashflow i 2. kvartal 2025. Det er nu blevet tydeligt, at selskabet skal færdiggøre en af de ovennævnte licensaftaler på tilfredsstillende vilkår inden udgangen af oktober 2024 for at opfylde selskabets behov for arbejdskapital fra begyndelsen af november 2024 og fremefter.             storage.mfn.se              xbrane-provides-update-on-the-ongoing-out-licensing-of-xdivane-nivolumab-biosimilar-candidate-and-xb003-cimzia-r-biosimilar-candidate-and-its-financial-position.pdf

Hvordan har du håndteret dine aktier i dette selskab, @Zolt? Jeg har først lige stiftet bekendtskab med dette firma, og det har været noget af en nedtur, især efter august 2023. Kraftig udvanding og cash burn, men kunne 2025 endelig blive deres år? Markedsværdien er nu ca. 30 mio. euro.

Svært at se nogen profitabel fremtid for denne Ximluci. Ud fra hvad jeg har undersøgt, er off-label Bevacizumab stadig billigere, og på den anden side er aflibercept og faricimab bedre og mere langtidsvirkende. Der er bare ikke nogen markedsniche.

xbrane.com              » Xbrane and STADA partner with Valorum Biologics to commercialize...                               XBRANE OG STADA INDGÅR PARTNERSKAB MED VALORUM BIOLOGICS OM KOMMERCIALISERING AF RANIBIZUMAB BIOSIMILÆR KANDIDAT I USA  Kunne man på baggrund af dette tænke, at det ser ret lovende ud med at opnå en FDA-godkendelse?

Xbrane Biopharma

” 2025 was a transformative year for Xbrane as we implemented a new strategic direction. Our strategy now focuses on two biosimilar candidates, Ximluci® and Xdivane™, enabling us to reduce our...

<div class="mfn-preamble"><p><strong>” 2025 was a transformative year for Xbrane as we implemented a new strategic direction. Our strategy now focuses on two biosimilar candidates, Ximluci® and Xdivane™, enabling us to reduce our cost base while maximizing shareholder value. The divestment of our Cimzia™ biosimilar project, together with parts of our organization, to Alvotech strengthened our balance sheet and significantly lowered our operating costs”, says Anders Tullgren, Chairman of the Board.</strong></p></div><div class="mfn-body"><p>Xbrane Biopharma AB’s annual report for 2025 is now available at the company’s website, www.xbrane.com.<br>The annual report includes the corporate governance report and the sustainability report for 2025. The Report is distributed to the shareholders and others that made such requests. It can also be ordered from Xbrane Biopharma at the following address:</p><p>Xbrane Biopharma AB<br>Scheeles väg 5<br>171 65 Solna<br>Sweden<br>Or via e-mail: ir@xbrane.com</p></div><div class="mfn-footer mfn-contacts mfn-a61f5cf72e83"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Martin Åmark, CEO<br>E: <a href="mailto:martin.amark@xbrane.com" rel="noopener">martin.amark@xbrane.com</a></p><p>Jane Benyamin, CFO/IR <br>E: <a href="mailto:jane.benyamin@xbrane.com" rel="noopener">jane.benyamin@xbrane.com</a></p></div><div class="mfn-footer mfn-about mfn-1cc8f17c2be2"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit&nbsp;<a href="http://www.xbrane.com" rel="noopener">www.xbrane.com </a>&nbsp;<br></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-vpml"><p><em>This information is information that Xbrane Biopharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-31 10:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a class="mfn-primary" href="https://storage.mfn.se/85615475-b24f-408e-bbab-ab1f3adcffd3/xbrane-ar-2025-eng.pdf" rel="noopener">Xbrane AR 2025 ENG</a><br><a href="https://storage.mfn.se/0b25f1ca-0fb5-4b5c-be65-fb6efa2060a8/xbra-2025-12-31-1-sv.xbri" rel="noopener">xbra-2025-12-31-1-sv</a><br><a href="https://storage.mfn.se/e46d1dbc-af77-4be6-8448-35782484ff11/xbra-2025-12-31-1-sv_preview.xhtml" rel="noopener">xbra-2025-12-31-1-sv_preview</a></p></div>

Xbrane has released the company's 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.